Nexalin Technology, Inc. (NXL)
NASDAQ: NXL · Real-Time Price · USD
1.260
+0.040 (3.28%)
May 9, 2025, 3:51 PM - Market open
Nexalin Technology Employees
Nexalin Technology had 6 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
6
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$28,120
Profits / Employee
-$1,267,864
Market Cap
16.76M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 6 | 0 | - |
Dec 31, 2023 | 6 | 0 | - |
Dec 31, 2022 | 6 | -4 | -40.00% |
Dec 31, 2021 | 10 | 6 | 150.00% |
Dec 31, 2020 | 4 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
NXL News
- 3 days ago - Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering - GlobeNewsWire
- 4 days ago - Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock - GlobeNewsWire
- 8 days ago - Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback - GlobeNewsWire
- 15 days ago - Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia - GlobeNewsWire
- 16 days ago - Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management - GlobeNewsWire
- 18 days ago - Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices - GlobeNewsWire
- 25 days ago - Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders - GlobeNewsWire
- 5 weeks ago - Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial - GlobeNewsWire